运用倾向性评分的方法探讨联合使用灯盏细辛注射液对冠心病患者临床结局的影响

灯盏细辛注射液是临床上治疗冠心病的常用中药注射剂,为探讨联合使用灯盏细辛注射液对冠心病临床结局的影响。该文基18 家三甲综合医院的 HIS(hospital information system,HIS)数据库所收集的所有联合使用了灯盏细辛注射液与未联合使用灯盏细辛注射液患者的信息、采用GBM倾向评分加权法,控制本研究数据中存在的大量混杂因素,采用Logistic 回归、倾向性评分加权的Logistic回归、带协变量调整的倾向性评分加权 Logistic 回归,分析使用灯盏细辛注射液对临床结局的影响。结果显示控制了混杂因素之后,联合使用灯盏细辛注射液相对于未联合使用灯盏细辛组其针对冠心病患者的死亡率存在统计学差异。说明联合使用灯盏细辛能降低冠心病患者的死亡率,但鉴于该文属于回顾性的研究,可能存在大量未知的混杂因素,该研究结果仍有待前瞻性研究做进一步证实。

Exploration of clinical outcomes on coronary heart disease of parenterally administered Dengzhan Xixin using propensity score

Parenterally administered Dengzhan Xixin is a common parenterally administered Chinese medicine for the treatment of coronary heart disease. The present research explored the application of parenterally administered Dengzhan Xixin on the clinical outcome of coronary disease. Hospital information system (HIS) data from 18 national, general hospitals was collected. Patients given parenterally administered Dengzhan Xixin in addition to other medications were compared with those not receiving it. General boosted method (GBM) and propensity score weighting was used to control for confounding variables between the groups. Logistic regression, and concomitant variable logistic regression of propensity score weighting were used to analyze the balanced confounding variable. Results showed that there was a statistically significant difference between the groups in death rate. The combined application of parenterally administered Dengzhan Xixin can lower the death rate from coronary disease. However, there are still a large amount of unknown confounding variable to take into account and the present research is a retrospective study. Therefore, prospective studies are warranted.